The U.S. Food and Drug Administration (FDA) announced that Baxter is recalling two lots of its 0.9% Sodium Chloride Injection due to the potential presence of fiberglass particulate matter. This recall addresses a serious health risk for patients receiving the intravenous solution.
Intravenous administration of solutions containing fiberglass can lead to severe adverse health consequences, including blood vessel blockage, clotting, pulmonary embolism, permanent organ damage, or death. Other potential issues include local vein irritation, inflammatory reactions, aggravation of existing infections, and allergic reactions. The affected product was distributed between July 31, 2026, and August 3, 2026, to healthcare providers and distributors in 14 U.S. states, including Florida, Illinois, and New York. As of August 25, 2026, Baxter has not received any reports of adverse events related to this issue.
The recalled product is used as a source of water and electrolytes and as a priming solution in hemodialysis procedures. Consumers are advised to immediately discontinue use of and return all affected units. Those who have experienced problems potentially related to the drug should contact their physician or healthcare provider. Baxter Healthcare Center for Service can be reached at 888-229-0001 for questions regarding the recall.